Observational studyRMD open2026
Early methylprednisolone pulses and prevention of long-term damage accrual in active systemic lupus erythematosus: a propensity score analysis of the Lupus-Cruces-Bordeaux cohort.
Observational study in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMethylprednisolone pulses (MP) help achieve prolonged remission in patients with moderate-severe systemic lupus erythematosus (SLE), but their potential effect in reducing damage accrual has not been addressed. This study aims to disclose whether MP given within the first year of follow-up could impact long-term damage accrual.
methodsObservational study using clinical care data of patients included in the Lupus-Cruces-Bordeaux cohort, expanded with patients from the historic Lupus Cruces cohort, with a follow-up time ≥5 years and up to 10 years. The primary outcome was the presence of irreversible organ damage or death for any cause during the whole follow-up time; the early outcome was set at 5 years. In addition, specific SLE-related and GC-related, cardiovascular and other forms of damage were also assessed as outcomes. The effect of MP was evaluated by Kaplan-Meier survival curves and propensity score (PS)-adjusted Cox models, in the whole cohort and in groups of mild activity (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) <6) and moderate-severe activity (SLEDAI≥6).
results469 patients were included, of whom 99 (21%) received MP. In the PS-adjusted Cox models, MP was associated with a significantly reduced risk for the primary outcome (adjusted HR 0.63, 95% CI 0.40 to 0.98, p=0.044), with the effect being significant also at 5 years (adjusted HR 0.61, 95% CI 0.37 to 0.98, p=0.042). The stratified analyses revealed that the benefit was restricted to the group of patients with moderate/severe activity and mainly in lupus and glucocorticoid-related damage items.
conclusionsThis study supports the role of the early MP in reducing long-term damage accrual and death, especially among patients with moderate/severe activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.